AstraZeneca: results of test for gastric cancer drug
(CercleFinance.com) - AstraZeneca has announced the results of the Destiny-Gastric01 positive phase II registration trial.
The trial has met its primary endpoint and the key secondary endpoint for overall survival in previously treated HER2-positive metastatic gastric cancer patients.
The group said, "Results from the positive registrational Phase II trial showed AstraZeneca's and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan), achieved a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS) in patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy."
Gilles Gallant, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo, said, "Our development plan remains on track in gastric cancer, including an initial regulatory application in Japan where gastric cancer is highly prevalent, and where SAKIGAKE designation has been granted for this indication."
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The trial has met its primary endpoint and the key secondary endpoint for overall survival in previously treated HER2-positive metastatic gastric cancer patients.
The group said, "Results from the positive registrational Phase II trial showed AstraZeneca's and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan), achieved a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS) in patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy."
Gilles Gallant, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo, said, "Our development plan remains on track in gastric cancer, including an initial regulatory application in Japan where gastric cancer is highly prevalent, and where SAKIGAKE designation has been granted for this indication."
Copyright (c) 2020 CercleFinance.com. All rights reserved.